Published in Virus Weekly, September 5th, 2006
"The purpose of this study was to determine the efficacy of novel recombinant AAV vector constructs in correcting metabolic defects in the liver in two strains of ornithine transcarbamylase (OTC)-deficient mice (spf and spf-ash)," wrote D. Moscioni and colleagues, University of Pennsylvania.
"AAV vectors expressing mouse OTC were produced with capsids from AAV2 and the novel serotypes AAV7, 8, and 9. OTC-deficient...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly